|
|
|
Journalists
Press releases
Press releases 2006
- To print this page, please use the File menu or press simultaneously ctrl + p keys.
- Send this page
Press releases are intended to journalists, analysts and investors.
Canadian Federal Court of Appeals rules in sanofi-aventis’ favor in the Canadian Plavix Notice of Compliance proceedings
December 28, 2006
Sanofi pasteur influenza vaccine production tops 170 million doses in 2006
December 20, 2006
Sanofi-aventis statement regarding U.S. FDA Joint Advisory Committee recommendation for Ketek® (telithromycin)
December 15, 2006
New organization announced for January 1st, 2007
December 14, 2006
Taxotere®-based regimens with Herceptin® in women with early-stage HER2-positive breast cancer demonstrate the highest reduction in the risk of death to date and provide a treatment option without anthracyclines
December 14, 2006
New study shows Clexane® / Lovenox® (enoxaparin sodium injection) is more effective than unfractionated heparin (UFH) for preventing the risk of venous thromboembolism (VTE) in patients with acute ischemic stroke
December 12, 2006
Idraparinux shows encouraging results in Van Gogh clinical trials program
December 10, 2006
Rimonabant update in the United States
December 8, 2006
Preliminary Injunction Against Apotex Upheld on Appeal
December 8, 2006
New data shows ACOMPLIA® (rimonabant) benefited patients with type 2 diabetes by improving blood sugar control, reducing weight and acting on other cardiometabolic risk factors
December 5, 2006
Sanofi-aventis receives pediatric exclusivity for AMBIEN® and AMBIEN® CR
November 29, 2006
Sanofi pasteur completes shipment of 50 million doses of influenza vaccine
November 27, 2006
Sanofi pasteur signs contract with U.S. government for stockpile of new type of H5N1 pre-pandemic vaccine
November 20, 2006
Sanofi-aventis, Innogenetics, and Inserm to collaborate on Alzheimer’s disease
November 13, 2006
Sweden grants reimbursement of Acomplia™ (rimonabant) for overweight patients with associated risk factors
November 10, 2006
Acomplia™ receives 1st marketing authorisation in the North American continent
November 9, 2006
First 9 months of 2006: Sales growth of 2.6% on a comparable basis - Adjusted EPS growth of 15.0%, or 7.5% excluding selected items
October 31, 2006
The Lancet publishes RIO-Diabetes study
October 27, 2006
New Head of sanofi-aventis Communications Department
October 26, 2006
The commercial subsidiary of sanofi-aventis in France is presenting a reorganisation plan resulting in the loss of 504 posts
October 25, 2006
Sanofi-aventis objects to the recommendation of the German Federal Joint Committee (“Gemeinsamer Bundesausschuss” – “G-BA”) regarding Acomplia
October 18, 2006
Sanofi Pasteur H5N1 pre-pandemic vaccine neutralizes additional circulating H5N1 virus
October 18, 2006
Taxotere® receives U.S. FDA approval for the treatment of patients with head and neck cancer
October 18, 2006
Sanofi-aventis has sold its entire stake in Rhodia
October 17, 2006
Sanofi-aventis announces the sale of its stake in Rhodia
October 17, 2006
Positive interim efficacy results from large randomized adjuvant gastric cancer trial
October 13, 2006
Sanofi-aventis strengthens its commitment with the World Health Organization (WHO) to fight neglected tropical diseases
October 10, 2006
Childhood cancers: second call for projects "My Child Matters"
October 2, 2006
Sanofi-aventis and UCB sign a co-promotion agreement for Xyzal® in the United States
September 25, 2006
TAXOTERE® receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval in the European Union for head and neck cancer
September 22, 2006
Plavix® Preliminary Injunction Appeal
September 21, 2006
Sanofi pasteur broadens pandemic preparedness with first clinical trial of novel cell based H7N1 vaccine
September 19, 2006
Sanofi-aventis prevails in arbitration against Rhodia
September 13, 2006
New Head of sanofi-aventis Human Resources Department
September 11, 2006
European commission expands indication for PLAVIX® (clopidogrel bisulfate) offering new option for patients with most severe type of heart attack
September 7, 2006
Sanofi-aventis withdraws European application for marketing authorization for dronedarone (MULTAQ™) in the treatment of Atrial Fibrillation/Atrial Flutter
September 7, 2006
New clinical data show enoxaparin significantly reduces the risk of repeat heart attacks and stroke in patients undergoing percutaneous coronary intervention (PCI)
September 4, 2006
Preliminary injunction ordered in PLAVIX® patent infringement case - Apotex to halt sales of unauthorized generic
September 1, 2006
Revised guidance for 2006
September 1, 2006
New trial date set for Lovenox® patent infringement suit
August 31, 2006
Sanofi-aventis receives a non approvable letter from the FDA for dronedarone (MULTAQ™) in the treatment of Atrial Fibrillation/Atrial Flutter - New filing expected during the first semester of 2008
August 31, 2006
FDA approves new indication for PLAVIX® (clopidogrel bisulfate) offering new option for patients with most severe type of heart attack
August 17, 2006
Motion filed for preliminary injunction in PLAVIX® patent infringement case
August 14, 2006
Trial date set for LOVENOX® patent infringement suit
August 10, 2006
Update regarding PLAVIX® patent infrigement case
August 8, 2006
Availability on-line of the Group’s interim report for the first half of 2006
August 4, 2006
First half of 2006: Sales growth of 7.7% on a reported basis and 4.5% on a comparable basis - Adjusted EPS growth of 32.9%, or 16.1% excluding selected items
August 2, 2006
PLAVIX® litigation settlement fails to receive antitrust clearance from states attorneys general
July 28, 2006
Update on PLAVIX® litigation settlement
July 27, 2006
Sanofi-aventis responds to the emergency request for humanitarian aid to Lebanon
July 20, 2006
Sanofi-aventis and Taiho sign an agreement for the development and marketing of an oral anticancer agent: S-1
July 3, 2006
Sanofi-aventis announces update to KETEK® (telithromycin) U.S. prescribing information
June 29, 2006
Update on PLAVIX® litigation settlement
June 25, 2006
ACOMPLIA® (rimonabant) receives marketing authorisation in the European Union
June 21, 2006
New study shows insulin glargine (LANTUS®) as effective and better tolerated than the prandial insulin lispro in initiating insulin therapy in type 2 diabetes
June 13, 2006
New study shows an innovative mealtime insulin dosing algorithm may provide a safe and effective alternative to carbohydrate counting for patients with type 2 diabetes
June 10, 2006
Study findings presented on TAXOTERE® regimens in head and neck, lung and breast cancer
June 7, 2006
Studies evaluating ELOXATIN®-based regimens in gastrointestinal cancers presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO)
June 5, 2006
Results of a meta-analysis show benefits of Taxotere® (docetaxel) regimens in patients with advanced non-small cell lung cancer (NSCLC)
June 3, 2006
General Meeting of Shareholders
June 1, 2006
New Eloxatin® and Taxotere® data in several tumor types to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO)
May 30, 2006
Adjuvanted formulation of Sanofi Pasteur H5N1 pandemic influenza vaccine candidate demonstrates significant immune response
May 11, 2006
PLAVIX® (clopidogrel) launched in Japan
May 9, 2006
First quarter of 2006: Sales growth of 9.6% on a reported basis and 4.9% on a comparable basis. 52.8% growth in adjusted EPS and 19.8% excluding selected items.
May 5, 2006
Acomplia® (rimonabant) recommended for approval in the European Union
April 28, 2006
Transfer of all Japanese rimonabant rights to Sanofi-aventis
April 12, 2006
Appeals court rules in Sanofi-aventis’ favor in the U.S. Lovenox® (enoxaparin sodium) patent infringement case
April 10, 2006
Lantus®: publication of the LANMET study results
April 3, 2006
Filing of the 2005 U.S. Form 20-F and French ''Document de Référence''
March 31, 2006
Sanofi-aventis acquires 24.876% of Zentiva and becomes its largest shareholder
March 27, 2006
TAXOTERE® receives positive opinion from the Committee for Medicinal Products for Human Use recommending approval in the European Union for metastatic stomach cancer
March 24, 2006
TAXOTERE® receives U.S. FDA approval for use in advanced stomach cancer
March 23, 2006
Sanofi-aventis and Bristol-Myers Squibb announce agreement to settle U.S. Plavix® litigation with Apotex subject to certain conditions
March 21, 2006
Press release - Plavix®: Questions and Answers
March 21, 2006
Agreement between Sanofi-aventis and Roche to produce shikimic acid
March 16, 2006
New study furthers understanding of the role of dual antiplatelet therapy in the prevention of atherothrombotic events, including heart attack, stroke or cardiovascular death in broad population
March 12, 2006
Rescheduling of the trial date in the United States PLAVIX® litigation
February 28, 2006
Apidra® – A New Rapid-Acting Insulin Analog – is Now Available in the United States for Hyperglycemia in Adults with Type 2 and Type 1 Diabetes
February 28, 2006
Strong growth of 25.7% in 2005 adjusted EPS - Nearly 90% of synergies delivered by end 2005 - Dividend increased by 26.7%
February 24, 2006
Sanofi-aventis received from the FDA an approvable letter for rimonabant for weight management and a non approvable letter for smoking cessation
February 17, 2006
The Journal of the American Medical Association publishes the RIO-North America study
February 14, 2006
Sanofi-aventis voluntarily recalls 30 batches of enoxaparin syringes as a precautionary measure
February 10, 2006
Sanofi pasteur delivers more H5N1 vaccine for U.S. government pandemic initiatives
February 6, 2006
''My child matters'': launch of a mobilisation campaign against childhood cancer in emerging countries
January 31, 2006
Dynamic growth in 2005 full-year consolidated net sales: up 9.3% on a comparable basis - Excellent performance from vaccines: up 26.9% on a comparable basis - 2005 adjusted earnings guidance raised - Approval of Plavix® in Japan
January 30, 2006
Xaliproden: final results of the Xenox clinical trial announced
January 28, 2006
PLAVIX®: Sanofi-aventis statement
January 24, 2006
PLAVIX® approved in Japan
January 24, 2006
FDA grants priority review to PLAVIX® (clopidogrel bisulfate) supplemental new drug application (sNDA) for additional type of heart attack
January 18, 2006
Pfizer to purchase sanofi-aventis rights to EXUBERA® in application of change of control clauses
January 13, 2006
FDA issues a written request for pediatric studies for zolpidem
January 11, 2006
|
|
